DE602006000381D1 - Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer - Google Patents

Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer

Info

Publication number
DE602006000381D1
DE602006000381D1 DE602006000381T DE602006000381T DE602006000381D1 DE 602006000381 D1 DE602006000381 D1 DE 602006000381D1 DE 602006000381 T DE602006000381 T DE 602006000381T DE 602006000381 T DE602006000381 T DE 602006000381T DE 602006000381 D1 DE602006000381 D1 DE 602006000381D1
Authority
DE
Germany
Prior art keywords
molecular weight
less
release
fraction content
base material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006000381T
Other languages
English (en)
Other versions
DE602006000381T2 (de
Inventor
Tatsuaki Miyaji
Makoto Sato
Tamaki Murayama
Yohei Hoashi
Hisae Saito
Takao Okada
Yukari Imamura
Yoshimichi Fujiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nipro Corp
Original Assignee
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipro Corp filed Critical Nipro Corp
Publication of DE602006000381D1 publication Critical patent/DE602006000381D1/de
Application granted granted Critical
Publication of DE602006000381T2 publication Critical patent/DE602006000381T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
DE602006000381T 2005-04-28 2006-04-25 Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer Active DE602006000381T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005131893 2005-04-28
JP2005131893 2005-04-28

Publications (2)

Publication Number Publication Date
DE602006000381D1 true DE602006000381D1 (de) 2008-02-14
DE602006000381T2 DE602006000381T2 (de) 2008-12-18

Family

ID=36952555

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006000381T Active DE602006000381T2 (de) 2005-04-28 2006-04-25 Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer

Country Status (4)

Country Link
US (1) US7342048B2 (de)
EP (1) EP1716847B1 (de)
AT (1) ATE382337T1 (de)
DE (1) DE602006000381T2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
RU2427383C2 (ru) 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи Фармацевтические композиции с повышенной стабильностью
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
US11059869B2 (en) 2011-03-23 2021-07-13 Elixirgen, Llc Compositions for enhancing the pluripotency of stem cells
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
CA2835825C (en) 2011-05-13 2021-03-23 Minoru S.H. Ko Use of zscan4 and zscan4-dependent genes for direct reprogramming of somatic cells
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
NZ712334A (en) 2013-03-15 2021-07-30 Elixirgen Therapeutics Inc Methods of using zscan4 for rejuvenating human cells
AU2014248090B2 (en) 2013-04-03 2018-08-02 N-Fold Llc Novel nanoparticle compositions
MX2016005101A (es) 2013-10-21 2017-01-09 Salk Inst For Biological Studi Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
JP6625071B2 (ja) 2014-03-07 2019-12-25 ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 慢性疼痛用のナトリウムチャネルを標的とする非麻薬性ｃｒｍｐ２ペプチド
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
AU2019252658B2 (en) 2018-04-12 2023-09-14 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
EP3856761A1 (de) 2018-09-24 2021-08-04 Krystal Biotech, Inc. Zusammensetzungen und verfahren zur behandlung des netherton-syndroms
US20210395775A1 (en) 2018-09-26 2021-12-23 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
CN113454105A (zh) 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
US20230118087A1 (en) 2019-09-03 2023-04-20 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
CN110882222B (zh) * 2019-12-05 2021-12-03 北京博恩特药业有限公司 颗粒组合物及制备方法和应用
US20210189427A1 (en) 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
CN111658620B (zh) * 2020-04-30 2022-04-19 天津医科大学口腔医院 一种透明质酸-帕瑞昔布plga微球及其制备方法和应用
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
EP4314028A1 (de) 2021-04-02 2024-02-07 Krystal Biotech, Inc. Virale vektoren für die krebstherapie

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328204A (en) 1977-03-02 1982-05-04 Ethicon, Inc. Absorbable polymer-drug compounds and method for making same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60181029A (ja) 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
JP3168263B2 (ja) 1984-07-06 2001-05-21 和光純薬工業株式会社 新規重合体及びこれを用いた医薬
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1236641A (en) 1984-07-06 1988-05-10 Motoaki Tanaka Copolymer of lactic acid and glycolic acid and method for producing same
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
CA2040141C (en) * 1990-04-13 2002-05-14 Minoru Yamada Biodegradable high-molecular polymers, production and use therof
JP3254449B2 (ja) 1990-04-13 2002-02-04 武田薬品工業株式会社 生体内分解型高分子重合物
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5614390A (en) 1996-06-14 1997-03-25 Becton, Dickinson And Company Species-specific detection of Mycobacterium kansasii
EP0839525B1 (de) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter Freisetzung
HUP0100221A3 (en) 1998-01-16 2002-11-28 Takeda Pharmaceutical Sustained release compositions, process for producing the same and utilization thereof
PT1693054T (pt) 2000-08-07 2016-07-07 Takeda Pharmaceuticals Co Polímero de ácido láctico e processo para a sua produção
JP3902518B2 (ja) 2001-06-29 2007-04-11 武田薬品工業株式会社 徐放性組成物用乳酸−グリコール酸重合体の製造法
JP5188670B2 (ja) 2001-06-29 2013-04-24 武田薬品工業株式会社 徐放性組成物およびその製造法
JP2004155792A (ja) 2001-06-29 2004-06-03 Takeda Chem Ind Ltd 徐放性組成物およびその製造法
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same

Also Published As

Publication number Publication date
US20060246139A1 (en) 2006-11-02
EP1716847B1 (de) 2008-01-02
DE602006000381T2 (de) 2008-12-18
US7342048B2 (en) 2008-03-11
EP1716847A1 (de) 2006-11-02
ATE382337T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
ATE382337T1 (de) Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
BRPI0812064B8 (pt) formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica
CY1115707T1 (el) Στερεα σταθεροποιημενα θεραπευτικα συστηματα ταχειας και/ή τροποποιημενης απελευθερωσης για τη χορηγηση απο του στοματος υγρων δραστικων ουσιων, εκδοχων ή τροφιμων
WO2009132265A3 (en) Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
CY1117889T1 (el) Πολυμερες γαλακτικου οξεος και διεργασια για την παραγωγη αυτου
MX2007000009A (es) Forma farmaceutica oral, protegida frente al abuso.
RS52463B (en) PHARMACEUTICAL DOSAGE FORMS ABUSE-RESISTANT CONTAINING OPIOID ANALGETIC
WO2006099514A3 (en) Drug delivery compositions and related methods
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
CO5570662A2 (es) Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
NZ601200A (en) Pharmaceutical dosage forms comprising poly(epsilon-caprolactone)
BR0002880A (pt) Composição farmacêutica de liberação controlada termoformável sólida
MY161620A (en) Oral care formulations that enhance amount of soluble zinc
MX336861B (es) Formulacion de farmaco resistente al abuso.
BRPI0620185B8 (pt) formulação farmacêutica, comprimidos, e, processo para a preparação de uma formulação farmacêutica
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
BRPI0510034A (pt) forma de dosagem para distribuição de múltiplas formas de fármacos
UA93530C2 (ru) Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения
PE20030066A1 (es) Composicion de liberacion controlada y metodo para producirla
GEP20115206B (en) Novel piperidine carboxylic acid amide derivatives
JP2015172095A5 (de)
BR0313428A (pt) Composições farmacêuticas de drogas semi-ordenados e polìmeros
TN2009000476A1 (en) Slow release pharmaceutical composition made of microparticles

Legal Events

Date Code Title Description
8364 No opposition during term of opposition